Oral NLRP3 inhibitor BGE-102 on track for Phase 1 initiation in 2H 2025 with initial data by year-end
BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates
Seeking Alpha / 13 hours ago 5 Views
Seeking Alpha / 13 hours ago 5 Views
Oral NLRP3 inhibitor BGE-102 on track for Phase 1 initiation in 2H 2025 with initial data by year-end
Comments